Cargando…

Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections

Bacterial biofilms are highly recalcitrant to antibiotic therapies due to multiple tolerance mechanisms. The involvement of Pseudomonas aeruginosa in a wide range of biofilm-related infections often leads to treatment failures. Indeed, few current antimicrobial molecules are still effective on toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivares, Elodie, Badel-Berchoux, Stéphanie, Provot, Christian, Prévost, Gilles, Bernardi, Thierry, Jehl, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962142/
https://www.ncbi.nlm.nih.gov/pubmed/31998248
http://dx.doi.org/10.3389/fmicb.2019.02894
_version_ 1783488102065504256
author Olivares, Elodie
Badel-Berchoux, Stéphanie
Provot, Christian
Prévost, Gilles
Bernardi, Thierry
Jehl, François
author_facet Olivares, Elodie
Badel-Berchoux, Stéphanie
Provot, Christian
Prévost, Gilles
Bernardi, Thierry
Jehl, François
author_sort Olivares, Elodie
collection PubMed
description Bacterial biofilms are highly recalcitrant to antibiotic therapies due to multiple tolerance mechanisms. The involvement of Pseudomonas aeruginosa in a wide range of biofilm-related infections often leads to treatment failures. Indeed, few current antimicrobial molecules are still effective on tolerant sessile cells. In contrast, studies increasingly showed that conventional antibiotics can, at low concentrations, induce a phenotype change in bacteria and consequently, the biofilm formation. Understanding the clinical effects of antimicrobials on biofilm establishment is essential to avoid the use of inappropriate treatments in the case of biofilm infections. This article reviews the current knowledge about bacterial growth within a biofilm and the preventive or inducer impact of standard antimicrobials on its formation by P. aeruginosa. The effect of antibiotics used to treat biofilms of other bacterial species, as Staphylococcus aureus or Escherichia coli, was also briefly mentioned. Finally, it describes two in vitro devices which could potentially be used as antibiotic susceptibility testing for adherent bacteria.
format Online
Article
Text
id pubmed-6962142
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69621422020-01-29 Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections Olivares, Elodie Badel-Berchoux, Stéphanie Provot, Christian Prévost, Gilles Bernardi, Thierry Jehl, François Front Microbiol Microbiology Bacterial biofilms are highly recalcitrant to antibiotic therapies due to multiple tolerance mechanisms. The involvement of Pseudomonas aeruginosa in a wide range of biofilm-related infections often leads to treatment failures. Indeed, few current antimicrobial molecules are still effective on tolerant sessile cells. In contrast, studies increasingly showed that conventional antibiotics can, at low concentrations, induce a phenotype change in bacteria and consequently, the biofilm formation. Understanding the clinical effects of antimicrobials on biofilm establishment is essential to avoid the use of inappropriate treatments in the case of biofilm infections. This article reviews the current knowledge about bacterial growth within a biofilm and the preventive or inducer impact of standard antimicrobials on its formation by P. aeruginosa. The effect of antibiotics used to treat biofilms of other bacterial species, as Staphylococcus aureus or Escherichia coli, was also briefly mentioned. Finally, it describes two in vitro devices which could potentially be used as antibiotic susceptibility testing for adherent bacteria. Frontiers Media S.A. 2020-01-09 /pmc/articles/PMC6962142/ /pubmed/31998248 http://dx.doi.org/10.3389/fmicb.2019.02894 Text en Copyright © 2020 Olivares, Badel-Berchoux, Provot, Prévost, Bernardi and Jehl. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Olivares, Elodie
Badel-Berchoux, Stéphanie
Provot, Christian
Prévost, Gilles
Bernardi, Thierry
Jehl, François
Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections
title Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections
title_full Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections
title_fullStr Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections
title_full_unstemmed Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections
title_short Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections
title_sort clinical impact of antibiotics for the treatment of pseudomonas aeruginosa biofilm infections
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962142/
https://www.ncbi.nlm.nih.gov/pubmed/31998248
http://dx.doi.org/10.3389/fmicb.2019.02894
work_keys_str_mv AT olivareselodie clinicalimpactofantibioticsforthetreatmentofpseudomonasaeruginosabiofilminfections
AT badelberchouxstephanie clinicalimpactofantibioticsforthetreatmentofpseudomonasaeruginosabiofilminfections
AT provotchristian clinicalimpactofantibioticsforthetreatmentofpseudomonasaeruginosabiofilminfections
AT prevostgilles clinicalimpactofantibioticsforthetreatmentofpseudomonasaeruginosabiofilminfections
AT bernardithierry clinicalimpactofantibioticsforthetreatmentofpseudomonasaeruginosabiofilminfections
AT jehlfrancois clinicalimpactofantibioticsforthetreatmentofpseudomonasaeruginosabiofilminfections